🟢 Moderna is trading 4.04% up today on mRNA-1010 flu vaccine FDA decision date

Moderna is trading at $59.30 (+4.04%) as investors focus on the upcoming FDA decision date for its mRNA-1010 flu vaccine.

• The stock is also supported by recent Q2 results which demonstrated tighter cost control and a smaller-than-expected loss.
• While the broader biotech sector is trading higher, the move is primarily attributed to the near-term regulatory catalyst surrounding the company's flu program.